Experience with Holter monitoring during propranolol therapy for infantile hemangiomas.


BACKGROUND Although adverse events in children treated with propranolol have proven rare, the appropriate methods of assessing cardiovascular risk and monitoring for toxicity when the medication is used for infantile hemangiomas remain unclear. OBJECTIVE We sought to analyze Holter monitor reports of otherwise healthy patients on propranolol for infantile… (More)
DOI: 10.1016/j.jaad.2015.05.015